TLR7 and neoplasm: Furthermore, a Phase I/II clinical trial in patients with metastatic breast cancer indicated that the combination of local radiotherapy with topical TLR7 agonist application was not only safe and feasible but also induced systemic tumor responses in some patients, with a local objective response rate significantly higher than that of TLR7 agonist monotherapy (210).